NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) Covered Calls

You can sell covered calls on NOVELION THERAPEUTICS INC COMMON SHARES to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NVLN (prices last updated Wed 4:16 PM ET):

NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.10 +0.01 1.05 1.07 687K - 0.0B
Covered Calls For NOVELION THERAPEUTICS INC COMMON SHARES (NVLN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 2.5 0.00 1.07 0.0% 0.0%
Nov 16 2.5 0.00 1.07 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.